Current Opinion in Obstetrics and Gynecology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of obstetrics and gynecology is divided into ten sections that are reviewed once a year. Each section is assigned one or more Section Editors. They are the leading authorities in their area, who identify the most important topics at that time. Here we are pleased to introduce the Journal's Editor and Section Editor for this issue.
Jonathan S. Berek
Jonathan S. Berek, MD, MMSc, is the Laurie Kraus Lacob Professor at Stanford University, Stanford University School of Medicine; Director, the Stanford Women's Cancer Center; and Senior Advisor, Stanford Cancer Institute, USA. He is the Executive Director, Stanford Health Communication Initiative, Stanford Center for Health Education, Stanford University. He served as the Chair of the Stanford Department of Obstetrics and Gynecology from 2005–2017.
Dr Berek is well known as a scholar, clinician, researcher and educator in the field. He is highly regarded for his research on the clinical management of gynecologic cancers and translational research related to these malignancies. He has published over 340 research papers, and several hundred contributed articles, book chapters and monographs. He is especially noted for two of the leading books in the field, Berek & Hacker's Gynecologic Oncology, 7th edition, and Berek & Novak's Gynecology, 16th edition.
Dr Berek earned his undergraduate and graduate degrees from Brown University, USA, his Doctor of Medicine degree at Johns Hopkins University School of Medicine, USA, completed his residency at the Harvard Medical School, Brigham and Women's Hospital, USA, and his fellowship in Gynecologic Oncology at the UCLA School of Medicine, USA. For many years, he was a Professor and Vice Chair of Obstetrics and Gynecology at UCLA, where he was also the Chair of the College of Applied Anatomy.
Dr Berek is the Group Chair and Principal Investigator for the Cooperative Gynecologic Oncology Investigators (COGI), a member of the Gynecologic Cancer InterGroup (GCIG). He served as Principal Investigator for the Gynecologic Oncology Group (GOG) for more than two decades. His primary research interest is in the immunology and immunotherapy of ovarian cancer, and through the development of experimental models and clinical trials, his initial studies encouraged the development of innovative biologic therapy strategies. Through collaborative work, his group focuses on the development of monoclonal antibodies and targeted immunotherapies for ovarian cancer. Dr Berek has had grant support from the National Institute of Health (NIH) and the Ovarian Cancer Research Foundation (OCRF).
Dr Berek is the recipient of the prestigious Sherman Mellinkoff Award and the Excellence in Education Award by the David Geffen School of Medicine at UCLA, and the 2010 John C. Fremont Pathfinder Award. He is regularly listed among America's Best Doctors for Gynecology & Gynecologic Oncology. In 2019, he was given an award by the American Cancer Society in recognition of his lifetime of achievement and for his many contributions to women's cancer care and research.
He is board certified by the American Board of Obstetrics and Gynecology (ABOG), and the Division of Gynecologic Oncology. He is a Fellow in the American College of Obstetricians and Gynecologists (FACOG), the American College of Surgeons (FACS), and the American Society of Clinical Oncologists (FASCO). Dr Berek has served as an examiner for the American Board Obstetrics and Gynecology (ABOG) and for the Council on Resident Education in Obstetrics and Gynecology (CREOG).
Dr Berek is Past-President of the Council of University Chairs of Obstetrics and Gynecology (CUCOG), and Past President of the International Gynecologic Cancer Society (IGCS). His many honors include receiving the President's Award from the Society of Gynecologic Oncologists (SGO), serving as its Vice President in 1996–1997, and presenting numerous distinguished lectureships. Dr Berek has served on many national committees for the National Institutes of Health (NIH), the National Cancer Institute (NCI), the American College of Surgeons (ACS), the Society of Gynecologic Oncologists (SGO), the American College of Obstetricians and Gynecologists (ACOG), and the American Society of Clinical Oncology (ASCO). He is a member of the Society of Gynecologic Investigation (SGI), and the Society of Pelvic Surgeons (SPS).
He is the Editor-in-Chief of Current Problems in Obstetrics and Gynecology, Past Editor-in-Chief of ASCO Connections, and Senior Editor of the International Journal of Gynecologic Cancer. He has served as an Editor of Prolog and Précis for the American College of Obstetricians and Gynecologists, and on the editorial boards of the Journal of Clinical Oncology, Gynecologic Oncology, and the Journal of the Society for Gynecologic Investigation.
Gottfried E. Konecny
Gottfried E. Konecny is Professor of Medicine and Obstetrics and Gynecology at the University of California Los Angeles (UCLA), USA. He is the Lead Clinician for gynecologic oncology in the Department of Medicine at UCLA. He obtained his medical degree and completed his residency training in obstetrics and gynecology at the University of Munich, Germany. Following his specialist training, he focused on clinical breast cancer research and decided to move to the US to pursue postdoctoral studies in the laboratory of Dennis J. Slamon to participate in laboratory and clinical research that led to the approval of new breast cancer drugs such as trastuzumab and lapatinib. He subsequently undertook subspecialty training in gynecologic oncology by completing a gynecologic oncology fellowship at Mayo Clinic in Rochester Minnesota, USA.
In 2007 he was recruited back to the University of California as a group leader to the Department of Medicine and the Translational Oncology Research Laboratory of UCLA, to establish a preclinical and clinical drug development program for gynecologic malignancies. As a physician-scientist, his work primarily focuses on translating the revolution in our understanding of the molecular underpinnings of cancer into novel treatment approaches, in which the right patient is being treated with the right drug at the right time.